Synaptogenix (NASDAQ:TAOX) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Synaptogenix (NASDAQ:TAOX) from a hold rating to a sell rating in a research report released on Sunday morning,Wall Street Zen reports.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Synaptogenix in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Synaptogenix Price Performance

NASDAQ:TAOX opened at $4.56 on Friday. Synaptogenix has a one year low of $3.07 and a one year high of $10.00. The business has a fifty day moving average price of $3.91 and a 200-day moving average price of $4.32. The firm has a market capitalization of $34.12 million, a price-to-earnings ratio of -1.18 and a beta of 1.73.

Synaptogenix (NASDAQ:TAOX) last released its earnings results on Thursday, August 13th. The company reported ($1.83) earnings per share for the quarter. Synaptogenix had a negative net margin of 2,153.97% and a negative return on equity of 128.51%. The company had revenue of $0.09 million for the quarter.

About Synaptogenix

Synaptogenix, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases and disorders involving memory and cognitive function. The company has primarily investigated treatments designed to support synaptic function and neuronal health.

Its lead research program has centered on bryostatin-1, a naturally derived compound being studied for its potential to activate protein kinase C epsilon and improve cognitive function in patients with Alzheimer’s disease.